Webinar presented on September 25, 2024 by Silvia Comis, MD, head of Clinical Development at OSE Immunotherapeutics and Valentina Manzini, PhD, Project Coordinator Companion Diagnostics at GenDx
In this webinar Silvia Comis, MD, head of Clinical Development at OSE Immunotherapeutics present OSE2101(also known as Tedopi®) and the ARTEMIA clinical trial, a registrational Phase III clinical trial of OSE2101 in non-small cell lung cancer. OSE2101 is a therapeutic cancer vaccine developed by OSE Immunotherapeutics and designed to induce a specific lymphocyte response in the body that can fight cancers that express the antigens present in the vaccine. As the synthetic antigens in OSE2101 are specifically targeted to HLA-A2 (Human Leucocytes Antigen-A2 superfamily) receptors present on the surface of cells, the targeted therapy requires a companion diagnostic solution.
Valentina Manzini, PhD, Project coordinator Companion Diagnostics, provides a description of the companion diagnostic solution GenDx CDx Tedopi, developed to aid in the identification of HLA-A*02 positive subjects for the ARTEMIA trial, who may be eligible for treatment with OSE Immunotherapeutics’ investigational drug, OSE2101.
